Authors: (Teresa L. Johnson, The Johns Hopkins University, Baltimore, MD, USA)
Abstract: This chapter outlines the history of the groundbreaking chemopreventive research
carried out by Dr. Paul Talalay and colleagues. This research has led to clinical trials
examining the ability of Nrf2-activating compounds to ameliorate problems of oxidative
stress, inflammation, and environmental pollutants. Such trials are anticipated to have a
major impact in decreasing the burden of chronic diseases.